Clinical Trial Update: CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating CapeOX plus bevacizumab and an anti-PD1 antibody for microsatellite-stable locally advanced rectal/colorectal cancer; curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• Anti-PD1 antibody
• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Locally Advanced Colorectal Cancer | Phase 2 | Status: RECRUITING